

Kombiglyze® XR (saxagliptin/metformin, extended release) – First-time generic

- On August 9, 2023, Viatris launched an <u>AB-rated</u> generic version of AstraZeneca's <u>Kombiglyze</u> XR (saxagliptin/metformin, extended-release) tablets.
 - Sun received FDA approval of an <u>AB-rated</u> generic version of Kombiglyze XR on July 31, 2023; launch plans for this generic are pending.
- Kombiglyze XR is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate.
- Kombiglyze XR carries a boxed warning for lactic acidosis.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.